Showing results (541-550 of 552) with videos related to

Sort By:
Pageof 56
Therapeutic Advances in Urology|April 28, 2025
Renal cell cancer treatment: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) surgery-focused consensus updateStênio de Cássio Zequi, Anderson de Oliveira Galvão, André Costa Matos, et al.
Surgery|November 21, 2024
IMMUNOREACT 8: Immune markers of local tumor spread in patients undergoing transanal excision for clinically N0 rectal cancerGiulia Becherucci, Cesare Ruffolo, Melania Scarpa, et al.
Scientific Reports|November 30, 2024
IMMUNOREACT 9 metachronous rectal cancers have high HLA-ABC expression on healthy epithelium but a lower infiltration of CD3+ T cells than primary lesionsBeatrice Salmaso, Melania Scarpa, Valerio Pellegrini, et al.
Cancer|April 22, 2024
IMMUNOREACT 7: Regular aspirin use is associated with immune surveillance activation in colorectal cancerOttavia De Simoni, Melania Scarpa, Ignazio Castagliuolo, et al.
Clinical Genitourinary Cancer|October 20, 2022
"Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil"Denis L Jardim, Adriano Gonçalves E Silva, Alexandre Saad Fere Lima Pompeo, et al.
Journal of Clinical Medicine|December 17, 2024
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.
Human Mutation|March 8, 2012
Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathyJohann Böhm, Valérie Biancalana, Elizabeth T Dechene, et al.
Cancers|February 27, 2026
IMMUNOREACT 4: Peritumoral Microenvironment Associated with Anastomotic Leaks After Surgery for Rectal CancerOttavia De Simoni, Melania Scarpa, Francesco Cavallin, et al.
Cancers|June 26, 2026
Ill Fate of Rectal Mucinous Adenocarcinoma: A Defect in Immunosurveillance or a Mucin Coating Effect?-The IMMUNOREACT 20 StudyLorenzo Dell'Atti, Andromachi Kotsafti, Francesca Galuppini, et al.
American Journal of Therapeutics|July 23, 2026
Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life StudyAntonio Tursi, Giammarco Mocci, Franco Scaldaferri, et al.
Pageof 56